CJC-1295
Growth hormone–releasing hormone (GHRH) analog
Quick Answer
A synthetic peptide designed to mimic and extend the activity of growth hormone–releasing hormone, which stimulates the pituitary gland to release growth hormone. Exists in variants with and without a "drug affinity complex" (DAC) that extends its half-life — these variants should be distinguished when discussed, not treated as one compound.
Why People Are Interested
Popular in the growth-hormone-optimization conversation as a longer-acting alternative to older GHRH-pathway compounds, often discussed alongside ipamorelin as a "stack."
What People Hope It May Do
Increased growth hormone release for body-composition and recovery goals — a plausible mechanism, but one studied mostly in small or early-stage settings rather than large controlled trials. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Growth hormone secretion dynamics
Potential body-composition-related research questions (mostly community-driven interest rather than a deep clinical trial base)
How It May Work
Binds GHRH receptors in the pituitary to stimulate growth hormone release, similar to natural GHRH but with a longer duration of action than the native hormone.
What Human Research Shows
Limited public clinical trial data; most available human information comes from earlier-stage or smaller studies rather than large controlled trials of the kind supporting an FDA-approved product.
What Preclinical Research Shows
Growth-hormone-axis pharmacology research, with more extensive preclinical characterization than human data.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to CJC-1295 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving CJC-1295, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No comprehensive, controlled human safety database exists publicly at the scale of an approved drug. Effects related to growth hormone elevation generally are an active research and clinical-monitoring topic that requires licensed medical oversight, not consumer self-guidance.
Regulatory Status
Not FDA-approved. Not available as an approved prescription product for any indication; commonly found in the gray-market "research chemical" space, which this business does not sell into.
What We Still Don't Know
Long-term safety of sustained growth-hormone-axis stimulation outside a supervised clinical context, and whether real-world body-composition outcomes match the mechanism's promise.
Limitations of Evidence
Sparse controlled human data; variant (with/without DAC) is often not clearly distinguished in available sources, which is itself a data-quality problem worth flagging in any article.
Keep Researching
- Search ClinicalTrials.gov for CJC-1295
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Key Studies
Verified directly against the PubMed abstract via NCBI eutils (PMID 16352683) on 2026-10-11. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA, Journal of Clinical Endocrinology & Metabolism, 2006: two randomized, placebo-controlled, double-blind, ascending-dose trials (28 and 49 days) in healthy adults aged 21–61. A single injection produced dose-dependent increases in plasma GH of 2- to 10-fold for 6+ days and IGF-I of 1.5- to 3-fold for 9–11 days; estimated half-life 5.8–8.1 days, with IGF-I remaining elevated up to 28 days after repeated dosing. No serious adverse events reported. This trial used the long-acting DAC-bearing form of CJC-1295 (consistent with the multi-day half-life reported) — it specifically supports the DAC variant, not an undifferentiated claim about "CJC-1295" generally. No separate human pharmacokinetic verification was found for the non-DAC variant; that distinction should stay explicitly hedged rather than implied as covered by this trial.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683. Verified via NCBI eutils abstract fetch, 2026-10-11.
Last reviewed: 2026-10-11 (Key studies/References added and independently verified — see note above)
Last reviewed: 2026-10-11 (Key studies/References added and independently verified — see note above)
